Plus Therapeutics, Inc. announced on March 7, 2025, the publication of its ReSPECT-GBM Phase 1 clinical trial results in the peer-reviewed medical journal Nature Communications. The manuscript detailed the treatment of recurrent glioma with Rhenium (186Re) Obisbemeda.
The publication highlighted that Rhenium (186Re) Obisbemeda demonstrated safety, response, and potential efficacy for glioblastoma (GBM) patients. Patients receiving greater than 100 Gy of the therapy achieved a median overall survival of 17 months.
This survival rate is more than double the 8-month median overall survival typically seen with standard of care. The peer-reviewed validation is substantial for this clinical program, supporting the ongoing ReSPECT-GBM Phase 2 trial.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.